Stewart L. Fisher net worth and biography

Stewart Fisher Biography and Net Worth

Insider of C4 Therapeutics

Stew Fischer, Ph.D. joined C4 Therapeutics in May 2016 and has served as our Chief Scientific Officer since May 2018. Between May 2016 and May 2018, Stew served as our Senior Director of Discovery Sciences. Prior to joining C4 Therapeutics, Stew held senior leadership roles at the Broad Institute, including Director of Quantitative of Biochemistry and Enzymology, where he developed and implemented biochemical plans for therapeutic projects. He previously spent fifteen years at AstraZeneca in roles of increasing responsibility across target validation, drug discovery and clinical candidate support, including Executive Director of Infection Bioscience. Stew started his career at Hoffmann-La Roche as a Research Scientist after completing an NIH Post-Doctoral Fellowship at Harvard Medical School. Stew holds a Ph.D. in Organic Chemistry from the California Institute of Technology, and a B.A. in Chemistry from the University of Vermont.

How old is Stewart L. Fisher?: Dr. Fisher is currently 57 years old. There are 6 older executives and no younger executives at C4 Therapeutics. The oldest executive at C4 Therapeutics is Dr. Kenneth C. Anderson M.D., Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board, who is 73 years old. Learn More on Stewart L. Fisher's age.
How do I contact Stewart L. Fisher?: The corporate mailing address for Dr. Fisher and other C4 Therapeutics executives is , , . C4 Therapeutics can also be reached via phone at 617-231-0700 and via email at jane.urheim@sternir.com. Learn More on Stewart L. Fisher's contact information.
Has Stewart L. Fisher been buying or selling shares of C4 Therapeutics?: Stewart L. Fisher has not been actively trading shares of C4 Therapeutics during the last ninety days. Most recently, Stewart Fisher sold 18,104 shares of the business's stock in a transaction on Monday, August 2nd. The shares were sold at an average price of $45.00, for a transaction totalling $814,680.00. Learn More on Stewart L. Fisher's trading history.
Who are C4 Therapeutics' active insiders?: C4 Therapeutics' insider roster includes Adam Crystal (Insider), Stewart Fisher (Insider), Elena Prokupets (Director), Malcolm Salter (Director), and Jolie Siegel (Insider). Learn More on C4 Therapeutics' active insiders.
Are insiders buying or selling shares of C4 Therapeutics?: In the last year, insiders at the sold shares 2 times. They sold a total of 1,159 shares worth more than $3,650.85. The most recent insider tranaction occured on February, 18th when insider Scott N Boyle sold 669 shares worth more than $2,107.35. Insiders at C4 Therapeutics own 8.6% of the company. Learn More about insider trades at C4 Therapeutics.
Information on this page was last updated on 2/18/2025.

Stewart L. Fisher Insider Trading History at C4 Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/2/2021	Sell	18,104	$45.00	$814,680.00

Stewart L. Fisher Buying and Selling Activity at C4 Therapeutics

C4 Therapeutics Company Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $1.52

$1.39

$1.57

50 Day Range

MA: $2.71

$1.44

$3.74

2 Week Range

Now: $1.52

$1.40

$8.08

Volume

782,363 shs

Average Volume

1,399,591 shs

Market Capitalization

$107.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.99